News Releases

Year

24 Sep '20

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients

- Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients.

PDF Version

09 Sep '20

Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

-- Presentation to be webcast on Cortexyme’s website -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey

PDF Version

27 Aug '20

Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

- New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years SOUTH SAN FRANCISCO, Calif.

PDF Version

17 Aug '20

Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update

— GAIN Trial enrollment on track to complete in Q4 2020 — GAIN Trial interim analysis on schedule to complete by year end 2020 — Clinical pipeline expansion anticipated in 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 17, 2020-- Cortexyme, Inc.

PDF Version

14 Aug '20

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients

- Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 14, 2020-- Cortexyme, Inc.

PDF Version

06 Aug '20

Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020

Presentations to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 6, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey

PDF Version

29 Jul '20

Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020

-- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 29, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen

PDF Version

28 Jul '20

Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases

-- Researchers presented new preclinical data on atuzaginstat and the potential impact on cardiovascular disease and AD-associated neurodegeneration in two poster presentations at AAIC 2020 -- Cortexyme also presented phase 1b clinical data demonstrating atuzaginstat‘s therapeutic potential in

PDF Version

22 Jul '20

Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 22, 2020-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research

PDF Version

09 Jun '20

Cortexyme Announces “Atuzaginstat” Selected as First-in-Class Nonproprietary Name for COR388

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 9, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced that the

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 25